Soluble guanylate cyclase stimulators for the treatment of hypertension: Discovery of MK-2947

• Published in: Bioorganic & medicinal chemistry letters Vol. 30; no. 21; p. 127574
• Main Authors: Brockunier, Linda, Stelmach, John, Guo, Jian, Spencer, Tracy, Rosauer, Keith, Bansal, Alka, Cai, Sheng-Jian, Chen, Nancy, Cummings, John, Huang, Li, Johnson, Timothy, Levesque, Sonia, Luo, Lin, Maloney, Kevin, Metzger, Joseph, Mortko, Christopher, Ortega, Karen, Pai, Lee-Yuh, Pereira, Antonio, Salituro, Gino, Shang, Jackie, Shepherd, Cherrie, Sherrie Xu, Shiyao, Yang, Qifeng, Cui, Jisong, Roy, Sophie, Parmee, Emma, Raghavan, Subharekha
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-11-2020
• Subjects: cGMP; Heme-dependent sGC stimulators; Hypertension; MK-2947; Nitric oxide; NO-sGC-cGMP; sGC stimulators; SHR; Soluble guanylate cyclase; Hypertension; MK-2947; Nitric oxide; Soluble guanylate cyclase; cGMP; Heme-dependent sGC stimulators; sGC stimulators; SHR; NO-sGC-cGMP
• ISSN: 0960-894X; 1464-3405
• DOI: 10.1016/j.bmcl.2020.127574

[Display omitted]
The NO-sGC-cGMP signaling pathway plays an important role in the cardiovascular system. Loss of nitric oxide tone or impaired signaling has been associated with cardiovascular diseases, such as hypertension, pulmonary hypertension and heart failure. Direct activation of sGC enzyme independent of NO represents a novel approach for modulating NO signaling with tremendous therapeutic potential. Herein, we describe the design of a structurally novel class of heme-dependent sGC stimulators containing the 3,3-dimethylpyrrolidin-2-one moiety which resulted in the identification of the potent, selective stimulator 30 (MK-2947) for the treatment of hypertension.